Author:
Kim Woorim,Kim Tae Hyeok,Oh Soo Jin,Kim Hyun Jeong,Kim Joo Hee,Kim Hyoun-Ah,Jung Ju-Yang,Choi In Ah,Lee Kyung Eun
Abstract
AbstractToll-like receptor (TLR)-4 and TLR9 are known to play important roles in the immune system, and several studies have shown their association with the development of rheumatoid arthritis (RA) and regulation of tumor necrosis factor alpha (TNF-α). However, studies that investigate the association between TLR4 or TLR9 gene polymorphisms and remission of the disease in RA patients taking TNF-α inhibitors have yet to be conducted. In this context, this study was designed to investigate the effects of polymorphisms in TLR4 and TLR9 on response to TNF-α inhibitors and to train various models using machine learning approaches to predict remission. A total of six single nucleotide polymorphisms (SNPs) were investigated. Logistic regression analysis was used to investigate the association between genetic polymorphisms and response to treatment. Various machine learning methods were utilized for prediction of remission. After adjusting for covariates, the rate of remission of T-allele carriers of TLR9 rs352139 was about 5 times that of the CC-genotype carriers (95% confidence interval (CI) 1.325–19.231, p = 0.018). Among machine learning algorithms, multivariate logistic regression and elastic net showed the best prediction with the area under the receiver-operating curve (AUROC) value of 0.71 (95% CI 0.597–0.823 for both models). This study showed an association between a TLR9 polymorphism (rs352139) and treatment response in RA patients receiving TNF-α inhibitors. Moreover, this study utilized various machine learning methods for prediction, among which the elastic net provided the best model for remission prediction.
Funder
National Research Foundation of Korea
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Dadoun, S. et al. Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis. Joint Bone Spine 80, 29–33 (2013).
2. Coenen, M. J. H. & Gregersen, P. K. Rheumatoid arthritis: A view of the current genetic landscape. Genes Immun. 10, 101–111 (2009).
3. Raychaudhuri, S. et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat. Genet. 41, 1313–1318 (2009).
4. NIH.gov. Genetics Home Reference. Your Guide to Understanding Genetic Conditions. Rheumatoid arthritis. [updated 18 August 2020; cited 1 October 2020]. https://medlineplus.gov/genetics/condition/rheumatoid-arthritis/.
5. Gerriets, V. et al. Tumor Necrosis Factor Inhibitors. [Updated 2020 Jul 4]. In StatPearls https://www.ncbi.nlm.nih.gov/books/NBK482425/ (StatPearls Publishing, 2020).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献